17,969 Shares in Revance Therapeutics, Inc. (NASDAQ:RVNC) Purchased by Rpo LLC

Rpo LLC acquired a new stake in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) during the 4th quarter, Holdings Channel reports. The fund acquired 17,969 shares of the biopharmaceutical company’s stock, valued at approximately $55,000.

A number of other institutional investors and hedge funds have also bought and sold shares of RVNC. KLP Kapitalforvaltning AS bought a new position in shares of Revance Therapeutics in the fourth quarter worth approximately $74,000. Dynamic Technology Lab Private Ltd purchased a new position in Revance Therapeutics in the 3rd quarter worth approximately $88,000. Virtu Financial LLC bought a new position in Revance Therapeutics in the 3rd quarter valued at approximately $120,000. Intech Investment Management LLC purchased a new stake in Revance Therapeutics during the 3rd quarter valued at $231,000. Finally, Deltec Asset Management LLC bought a new stake in shares of Revance Therapeutics in the 4th quarter worth $304,000. 97.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on RVNC. StockNews.com started coverage on Revance Therapeutics in a report on Thursday. They set a “hold” rating on the stock. Mizuho decreased their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating for the company in a research report on Tuesday, December 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Finally, Barclays decreased their price objective on shares of Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating for the company in a report on Monday, December 23rd. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Price Performance

NASDAQ RVNC opened at $3.65 on Thursday. The company has a 50-day moving average price of $3.65 and a 200-day moving average price of $4.08. Revance Therapeutics, Inc. has a 52 week low of $2.30 and a 52 week high of $6.65. The firm has a market capitalization of $381.02 million, a P/E ratio of -1.89 and a beta of 0.90.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.